Literature DB >> 33515273

Dual-probe fluorescent biosensor based on T7 exonuclease-assisted target recycling amplification for simultaneous sensitive detection of microRNA-21 and microRNA-155.

Yanjie Zheng1, Jinyuan Chen2, You Li1,3, Yichun Xu1, Li Chen1, Wei Chen1,4, Ailin Liu1,4, Xinhua Lin5,6, Shaohuang Weng7.   

Abstract

Effective and simultaneous monitoring of the abnormal expression of certain microRNAs (miRNAs), especially for miRNA-21 and miRNA-155, can indicate drug resistance in lung cancer. In this work, T7 exonuclease (T7 Exo)-assisted target recycling amplification coupled with the extensive fluorescence quenching of graphene oxide (GO) was designed for the simultaneous detection of miRNA-21 and miRNA-155 using FAM- and ROX-labeled single-strand DNA probes. Through this method, the variable emission intensities of FAM and ROX caused by the introduction of miRNA-21 and miRNA-155, respectively, were obtained with high sensitivity. The method exhibited excellent analytical performance for simultaneous detection of miRNA-21 and miRNA-155 without cross-interference. The linear range was from 0.005 nM to 5 nM over three orders of magnitude, with detection limits as low as 3.2 pM and 4.5 pM for miRNA-21 and miRNA-155, respectively. Furthermore, the recovery (92.49-103.67%) and relative standard deviation (RSD < 4.8%) of the standard addition test of miRNA-21 and miRNA-155 in human plasma suggested the potential for drug resistance warning in clinical practice via this simple strategy. A homogeneous T7 Exo-assisted signal amplification combined with GO quenching platform was developed for accurate, sensitive and simultaneous analysis of miRNA-21 and miRNA-155 for drug resistance warning in lung cancer. This simple method exhibited a wide linear range and low LODs for miR-21 and miR-155.

Entities:  

Keywords:  Drug resistance warning; Dual-probe fluorescent biosensor; Simultaneous detection; microRNA-155; microRNA-21

Mesh:

Substances:

Year:  2021        PMID: 33515273     DOI: 10.1007/s00216-020-03121-6

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  34 in total

1.  A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.

Authors:  B T Li; A Drilon; M L Johnson; M Hsu; C S Sima; C McGinn; H Sugita; M G Kris; C G Azzoli
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

2.  The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts.

Authors:  Motonobu Saito; Aaron J Schetter; Steen Mollerup; Takashi Kohno; Vidar Skaug; Elise D Bowman; Ewy A Mathé; Seiichi Takenoshita; Jun Yokota; Aage Haugen; Curtis C Harris
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

3.  One DNA circle capture probe with multiple target recognition domains for simultaneous electrochemical detection of miRNA-21 and miRNA-155.

Authors:  Sai Xu; Yuanyuan Chang; Zhongyu Wu; Yunrui Li; Ruo Yuan; Yaqin Chai
Journal:  Biosens Bioelectron       Date:  2019-11-05       Impact factor: 10.618

Review 4.  Clinical utility of circulating non-coding RNAs - an update.

Authors:  Simone Anfossi; Anna Babayan; Klaus Pantel; George A Calin
Journal:  Nat Rev Clin Oncol       Date:  2018-09       Impact factor: 66.675

Review 5.  Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Authors:  Saoirse O Dolly; Dearbhaile C Collins; Raghav Sundar; Sanjay Popat; Timothy A Yap
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 6.  High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer.

Authors:  Miaomiao Yang; Hongchang Shen; Chen Qiu; Yang Ni; Liguang Wang; Wei Dong; Yida Liao; Jiajun Du
Journal:  Eur J Cancer       Date:  2012-10-22       Impact factor: 9.162

Review 7.  Clinical significance of miRNAs in autoimmunity.

Authors:  Lian Zhang; Haijing Wu; Ming Zhao; Christopher Chang; Qianjin Lu
Journal:  J Autoimmun       Date:  2020-03-14       Impact factor: 7.094

8.  MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN.

Authors:  Zhi-Li Liu; He Wang; Jing Liu; Zhao-Xia Wang
Journal:  Mol Cell Biochem       Date:  2012-09-06       Impact factor: 3.396

9.  Potential circulating miRNA signature for early detection of NSCLC.

Authors:  Ayda Arab; Morteza Karimipoor; Shiva Irani; Arda Kiani; Sirous Zeinali; Elham Tafsiri; Kambiz Sheikhy
Journal:  Cancer Genet       Date:  2017-08-07

Review 10.  Cell signaling and cancer: a mechanistic insight into drug resistance.

Authors:  Munmun Panda; Bijesh K Biswal
Journal:  Mol Biol Rep       Date:  2019-07-06       Impact factor: 2.316

View more
  2 in total

Review 1.  Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC).

Authors:  Parvaneh Sardarabadi; Amir Asri Kojabad; Davod Jafari; Cheng-Hsien Liu
Journal:  Biosensors (Basel)       Date:  2021-10-15

2.  One-Step Homogeneous Immunoassay for the Detection of Influenza Virus Using Switching Peptide and Graphene Quencher.

Authors:  Hong-Rae Kim; Ji-Hong Bong; Tae-Hun Kim; Seung-Shick Shin; Min-Jung Kang; Won-Bo Shim; Do Young Lee; Dong Hee Son; Jae-Chul Pyun
Journal:  Biochip J       Date:  2022-07-27       Impact factor: 4.229

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.